Scribe Therapeutics priced an upsized $128.7 million IPO, increasing the share count after an initial public offering launched at $15 per share. Underwriters led by Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo also received an option to add 30-day overallotment shares. In parallel with the IPO, Sanofi agreed to buy 500,000 shares for about $7.5 million, reinforcing an existing research collaboration that could total up to $1.5 billion in “biobucks.” Scribe says proceeds will support its lead in vivo, liver-targeted PCSK9 epigenetic silencing program STX-1150, already in a Phase 1 study (NCT07428473). The company also earmarked funds for STX-1400 and STX-1200, expanding its pipeline toward additional lipid-regulation targets. With IPO activity picking up through 2026, Scribe’s offering highlights investor demand for clinical-stage differentiated platforms. — Key takeaway: Sanofi’s concurrent placement links a large-cap partner directly to Scribe’s early clinical trajectory ahead of broader catalyst risk.